Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: James Perry who wrote (419)	8/25/1998 2:33:00 AM
From: John Zwiener	Read Replies (1) \| Respond to of 1025

Hi James, OT is an independent company based in Europe, maybe Sweden. No connection to Wohlstadter. OT is a fairly large company and a good reputation. Sam has indicated that a POC deal would be separate and after the central lab license is resolved with Roche, and not tied together. But on the other hand, there may be an understanding of what a POC deal would be. Presumably, if Roche is interested in a POC deal, this would follow relatively rapidly after a buyout of the central lab license was agreed on. Sam does have some smaller companies he owns, and Igen bought out one of them. I think it was mesoscale diagnostics. If I remember right, this company and Igen put up equal amounts of money to develop superminiturized diagnostic tests. Igen bought out the company for what mesoscale had already put up. There was also one with carbon filaments which Igen also bought for about the cost of development with no real premium that I could see. I'm not sure if I got the names of the companies right, or the products involved matched with the companies, but I did look to see if Sam profited from the deals, and I didn't see any of that.